Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price target increased by equities research analysts at Citigroup from $16.00 to $17.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup‘s price target suggests a potential upside of 118.37% from the company’s current price.
Other analysts have also issued reports about the stock. BTIG Research restated a “buy” rating and issued a $26.00 price objective on shares of Oric Pharmaceuticals in a report on Tuesday. Stifel Nicolaus increased their target price on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, October 26th. HC Wainwright increased their target price on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Leerink Partners began coverage on shares of Oric Pharmaceuticals in a research report on Monday, October 5th. They set an “outperform” rating and a $26.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, October 15th. Fourteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.33.
Get Our Latest Analysis on Oric Pharmaceuticals
Oric Pharmaceuticals Stock Performance
Shares of ORIC stock traded up $0.27 during trading hours on Tuesday, reaching $7.79. The company had a trading volume of 158,099 shares, compared to its average volume of 1,707,004. Oric Pharmaceuticals has a 12-month low of $7.23 and a 12-month high of $14.68. The company has a market capitalization of $806.92 million, a price-to-earnings ratio of -5.78 and a beta of 1.23. The stock has a fifty day moving average of $11.45 and a 200-day moving average of $10.99.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.05). On average, analysts forecast that Oric Pharmaceuticals will post -1.53 EPS for the current year.
Insider Activity at Oric Pharmaceuticals
In other news, CFO Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at approximately $955,945.32. The trade was a 52.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock worth $1,432,952 in the last ninety days. Company insiders own 5.70% of the company’s stock.
Hedge Funds Weigh In On Oric Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new position in Oric Pharmaceuticals in the 2nd quarter valued at about $38,000. Quantbot Technologies LP acquired a new stake in shares of Oric Pharmaceuticals during the second quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Oric Pharmaceuticals during the third quarter worth about $71,000. Bellevue Group AG purchased a new position in shares of Oric Pharmaceuticals in the third quarter valued at approximately $75,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Oric Pharmaceuticals in the second quarter valued at approximately $128,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
See Also
- Five stocks we like better than Oric Pharmaceuticals
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
